Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.leukres.2009.10.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development and alpha-testing of a patient decision aid for patients with chronic myeloid leukemia regarding dose reduction.
BMC Med Inform Decis Mak
December 2024
Department of Pharmacy, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, The Netherlands.
Background: Dose reduction of tyrosine kinase inhibitors (TKIs) is an option for some chronic myeloid leukemia (CML) patients to minimize side effects while maintaining efficacy. Shared decision-making (SDM) and patient decision aids (PDAs) are advocated to make informed choices such as reducing the dose of TKIs. This paper describes the development and alpha-testing of a PDA for patients with CML receiving TKI dose reduction.
View Article and Find Full Text PDFOutcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib.
Ann Hematol
November 2024
Hospital Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Universidad de Alcalá, Madrid, Spain.
Article Synopsis
- * Out of these patients, 8 experienced treatment intolerance with asciminib while 11 developed resistance; treatment strategies included dose adjustments of cTKIs or considering ponatinib despite previous non-candidacy.
- * The overall survival rate was 73% with the best outcomes for those intolerant to drugs (100%), while patients who progressed to advanced stages had a notably low survival rate (25%).
Late presentation of chronic myeloid leukaemia patients in a low-income country: the prognostic implications and impact on treatment outcome.
BMC Res Notes
September 2024
Department of Haematology and Blood Transfusion, Obafemi Awolowo University, Teaching Hospitals Complex, Ile-Ife, Nigeria.
Background: In Nigeria, since 2002, Imatinib mesylate (glivec) has been available freely to chronic myeloid leukaemia (CML) patients but only at a tertiary health care centre in the southwestern part of the country. Despite this, it is not readily accessible to many patients due to the distance and other challenges including low socioeconomic status and political problems, preventing timely access to specialist care. This study evaluated the effect of the baseline characteristics on the prognostic implication and treatment outcome of CML patients in Nigeria.
View Article and Find Full Text PDFImmunophenotypic and Cytogenetic Characteristics of Pediatric Acute Lymphoblastic Leukemia: A Burden Estimation Study from Eastern India.
Indian J Public Health
January 2024
Senior Resident, Department of Pediatric Medicine, Institute of Child Health, West Bengal, India.
Background: Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Immunophenotype (IPT) and cytogenetics are essential for diagnosis, risk stratification, and management for ALL.
Objectives: Evaluating the burden of immunophenotypic and cytogenetic profile of pediatric ALL patients.
An association between Dasatinib, elevated left atrial pressure and pleural effusion.
Int J Cardiol
September 2024
Victorian Heart Hospital, Monash Health, Melbourne, Victoria, Australia; Monash Cardiovascular Research Centre, Monash University, Melbourne, Victoria, Australia. Electronic address:
Background: Tyrosine kinase inhibitors (TKI), such as Dasatinib, are effective in the treatment of chronic myeloid leukemia (CML) but associated with development of pleural effusions (PE). The relationship between haemodynamic parameters identified on transthoracic echocardiogram (TTE) such as elevated estimated left atrial pressure (LAP), and PE development is unknown. This study aims to describe associations between Dasatinib, elevated LAP and PE.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!